Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort

অনুরূপ উপাদানগুলি

• Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
  অনুযায়ী: Shang-Gin Wu, অন্যান্য
  প্রকাশিত: (2017-07-01)
• Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
  অনুযায়ী: Wu, Shang-Gin, অন্যান্য
  প্রকাশিত: (2017)
• Effect of β-Blocker in Treatment-Naïve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs
  অনুযায়ী: Chang, Chia-Hao, অন্যান্য
  প্রকাশিত: (2020)
• The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
  অনুযায়ী: Wu, Shang-Gin, অন্যান্য
  প্রকাশিত: (2016)
• Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
  অনুযায়ী: Liang, Sheng-Kai, অন্যান্য
  প্রকাশিত: (2017)